Back

In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

31 August 2026 (09:40 - 09:50)
Organised by: Logo
Congress Presentation Part of: Improving care in cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Hui Yan

First affiliated Hospital at Zhejiang University School of Medicine, Hangzhou (China)

5 More presentations in this session

Presentation thumbnail
Novel blood-based biomarkers for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in patients heart failure with preserved ejection fraction
Doctor H. Gaggin (Boston, US)
Abstract Slides
Presentation thumbnail
Assessing generalizability of an AI model for cardiac amyloidosis detection in ECGs: interim results of a multi-centre, external validation study
Assistant Professor F. Ahmad (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran phase 3 studies
Assistant Professor A. Zaroui (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Prognostic value of CT-derived pectoralis muscle area in tafamidis-treated ATTRwt cardiomyopathy
Doctor K. Ayai (JP)
Abstract Slides Video
Presentation thumbnail
Recurrence of transthyretin amyloid cardiomyopathy following heart transplantation - a long term follow-up analysis
Doctor M. Poledniczek (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Improving care in cardiac amyloidosis
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 09:40 CET
You may be interested in
thumbnail
Congress Presentation
Gene editing: can CRISPR cure ATTR?
28 August 2026
thumbnail
Congress Presentation
CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy
28 August 2026
thumbnail
Congress Presentation
GenePHIT Phase 2 baseline characteristics: a double blind, placebo-controlled trial to assess safety and efficacy of AB-1002 gene therapy in heart failure with reduced ejection fraction
29 August 2026
thumbnail
Congress Session
Cardiac amyloidosis from epidemiology to treatment
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources